V-CARD

PHONE
+86 10 6582 9488
FAX
+86 10 6582 9499
|
|
Adrian
Emch
Counsel, Beijing
adrian.emch@hoganlovells.com
Adrian Emch practises antitrust, regulatory and trade law, with a particular focus on matters related to the European Union and to China. Adrian has broad experience in all aspects of competition law, including merger control, multi-jurisdictional merger filings, cartel investigations and antitrust counseling.
Adrian also advises on legal aspects of China-Latin American trade and investment.
Adrian is a lecturer of competition law and member of the faculty at Peking University's IP School. He frequently publishes and speaks on topics of EU and Chinese competition and regulatory law issues.
Prior to joining Hogan Lovells, Adrian completed an internship with the Directorate-General of Competition at the European Commission and was in private practice in Brussels and Beijing in the field of competition law.
REPRESENTATIVE EXPERIENCE
- Assisting BASF with the merger filing for its acquisition of specialty chemicals maker Cognis in China.
- Assisting Citigroup with a merger filing in China.
- Preparing merger notifications for several Western multinationals and Asian conglomerates in Greater China.
- Supporting ALSTOM in merger filings in China for various transactions.
- Advising one of the world's leading pharmaceutical companies on compliance of its distribution agreements with antitrust rules in Greater China.
- Giving advice in cartel proceedings before the European Commission and interviewing key company employees for discovery purposes.
- Coordinating analysis of need for foreign investment and national security filings in life sciences merger in 70 jurisdictions worldwide.
Hogan Lovells Publications
19 January 2012
"MOFCOM Gets Serious About Unreported M&A Transactions.", Hogan Lovells LLP
08 December 2011
"Life Sciences Antitrust and Competition Newsletter." Life Sciences: Competition & Antitrust Alert, Issue 18, Hogan Lovells
29 November 2011
"Strong Medicine for Law Breakers - NDRC's First Antitrust Action in the Pharmaceutical Sector under the Anti-Monopoly Law.", Hogan Lovells
18 November 2011
"Three “Firsts” – China’s Merger Control Process Is Moving On.", Hogan Lovells
07 November 2011
"MOFCOM Imposes Divestiture Obligation in Its Approval of Private Equity Transaction.", Hogan Lovells
28 July 2011
"U.S. and Chinese antitrust agencies sign memorandum of understanding to enhance cooperation." Antitrust, Competition and Economic Regulation Alert, Hogan Lovells
23 June 2011
"Hogan Lovells Antitrust, Competition and Economic Regulation Alert, China - June 2011.", Hogan Lovells
14 March 2011
"MOFCOM releases implementing rules on national security review.", Hogan Lovells
25 February 2011
"China's New National Security Review Procedures for Mergers and Acquisitions Involving Foreign Investors: A New Hurdle for Foreign Investors or China Just Putting Existing Practice To Paper?" China Alert, Hogan Lovells
12 January 2011
"Antitrust Competition and Economic Regulation E-alert - China: Newly Enacted NDRC and SAIC Rules May Usher In New Anti-Monopoly Enforcement Phase." Antitrust, Competition, and Economic Regulation Alert, Hogan Lovells
15 December 2010
"China Corporate Alert - China liberalizes foreign investment in medical services sector.", Hogan Lovells
02 December 2010
"Life Sciences: Competition and Antitrust Newsletter, Issue 17.", Hogan Lovells
Published Works
October 2011
"MOFCOM clears mining merger subject to conditions." IBA Antitrust Newsletter, International Bar Association
18 February 2011
"The antitrust enforcers' New Year resolutions." China Law & Practice, Hogan Lovells
13 October 2010
"Antitrust rules and standard setting; a new dawn in China?" Intellectual Property Magazine
09 September 2010
"MOFCOM's Stance On Novartis/Alcon." Law360, Portfolio Media, Inc.
May 2010
"China's cartel-buster flexes it's muscles.", Asian Counsel magazine
|
|
|